Related Experiment Video
Updated: Jan 8, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Current developments and future directions in androgen receptor targets using nano-based therapeutics for the
Nirali Shukla1, Anam Sami2, Deepshikha Rathore1
1Institute of Science, Nirma University, Ahmedabad, Gujarat, India.
Abstract:
Nanoformulated androgen receptor (AR) antagonists constitute a cutting-edge advancement in the treatment of AR-driven cancers by significantly enhancing the precision and effectiveness of therapy. These nanoparticle-based formulations are uniquely designed to simultaneously inhibit AR-driven transcription and critical signaling pathways involved in tumor progression and drug resistance, including PI3K/AKT and MAPK cascades. The distinctive properties of nanoparticles, such as improved bioavailability, controlled and sustained drug release, and active tumor targeting, enable these AR antagonists to achieve higher intratumoral concentrations and minimize off-target effects. This targeted delivery system not only overcomes common resistance mechanisms seen with conventional AR antagonists but also facilitates the co-delivery of multiple agents for synergistic therapeutic action. This review highlights how nanoformulated AR antagonists hold immense potential to transform cancer management by providing more effective, durable responses and a foundation for personalized, multi-pathway-targeted treatment strategies in advanced and resistant cancers. Their development addresses critical clinical challenges, offering a promising pathway to improve patient outcomes and fill significant gaps in current oncologic therapies.
Insights
Nanoformulated androgen receptor (AR) antagonists offer precise cancer treatment by targeting tumor pathways and overcoming resistance. These advanced nanoparticles improve drug delivery for better patient outcomes in AR-driven cancers.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Androgen receptor (AR)-driven cancers require targeted therapies.
- Conventional AR antagonists face challenges with drug resistance and off-target effects.
- Nanoparticle drug delivery systems offer potential solutions for enhanced cancer treatment.
Purpose of the Study:
- To review advancements in nanoformulated AR antagonists for cancer therapy.
- To highlight the mechanisms and benefits of nanoparticle-based AR inhibition.
- To discuss the potential of these formulations in overcoming drug resistance and improving patient outcomes.
Main Methods:
- Review of current literature on nanoformulated AR antagonists.
- Analysis of nanoparticle properties relevant to cancer drug delivery.
- Examination of mechanisms targeting AR-driven transcription and signaling pathways (PI3K/AKT, MAPK).
Main Results:
- Nanoformulated AR antagonists demonstrate enhanced bioavailability and controlled drug release.
- These systems achieve higher intratumoral concentrations, minimizing systemic toxicity.
- Nanoparticles facilitate co-delivery of multiple agents for synergistic effects and overcoming resistance.
Conclusions:
- Nanoformulated AR antagonists represent a significant advancement in treating AR-driven cancers.
- They offer a promising strategy for personalized, multi-pathway-targeted cancer therapies.
- This approach holds potential to improve treatment effectiveness and patient outcomes in advanced and resistant cancers.
